Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01055340 | A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED) | PHASE1 | COMPLETED | 12 | — | — | Apr 1, 2010 | Jun 1, 2010 | May 29, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| Treatment sequence 1 | EXPERIMENTAL | OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo |
| Treatment sequence 2 | EXPERIMENTAL | OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min |
| Treatment sequence 3 | EXPERIMENTAL | Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min |
| Treatment sequence 4 | EXPERIMENTAL | OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min |
| Treatment sequence 5 | EXPERIMENTAL | Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min |
| Treatment sequence 6 | EXPERIMENTAL | OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo |
| Name | Type | Description |
|---|---|---|
| Oxyntomodulin (OXM) | DRUG | Single infusion of OXM 3.0 pmol/kg/min by IV |
| Comparator: Oxyntomodulin (OXM) | DRUG | Single infusion of OXM 0.6 pmol/kg/min by IV |
| Comparator: Placebo [ hemaccel-containing saline] | DRUG | Single Placebo infusion of hemaccel-containing saline by IV |
Inclusion Criteria: * Subject is judged to be in good health based on medical history, physical examination, and laboratory safety tests * Subject has a Body Mass Index of ≥27 kg/m\^2 and ≤35 kg/m\^2 and weighs ≥70 kg at the prestudy (screening) visit * Subject has been a nonsmoker and/or has not u...